Study of XB010 in Subjects With Solid Tumors is a clinical research project aimed at testing a new medicine called XB010. This study is an *FIH* study, which means it's the first time the drug is being tested on humans. The study will check if the drug is safe and how the body responds to it. It will also see if the drug can help fight tumors when used alone or with another drug called pembrolizumab. The study has two parts: Dose-Escalation and Cohort-Expansion.

In the Dose-Escalation Stage, researchers find out the best dose of XB010, both alone and with pembrolizumab. The Cohort-Expansion Stage looks at how well XB010 works in different types of tumors and checks its safety more closely.

• The study is for people 18 years or older with advanced or hard-to-treat solid tumors.
• Participants must be able to follow the study rules and sign a consent form.
• They should have good organ function and be in good physical condition.

Participation may involve regular health checks and taking the study medication. It's important to talk to your doctor about possible risks and benefits before joining.